TRAX Stock — First Tracks Biotherapeutics

First Tracks Biotherapeutics (TRAX)

Updated October 16, 2026.

TRAX is a Stock. Total return is 172.0% over the past 0.6 years, 158.4 points ahead of SPY at 13.6%.

First Tracks Biotherapeutics is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline including anti-CD122 antagonists, T-cell-depleting antibodies, and dendritic cell-targeting therapies. The company does not currently have an established distribution schedule. This security appeals to investors with high risk tolerance interested in early-stage biotechnology development.

TRAX performance versus SPY

Price and return data through 2026-10-16.

Total return is 172.0% over the past 0.6 years, 158.4 points ahead of SPY at 13.6%.

TRAX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/10/2026

Distribution frequency

None

Last close

$34.46 (as of 2026-10-16)

Market cap

$1,231,284,850

Average volume

1041417.0

Payout ratio

0.0%

EPS

$-4.71

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider TRAX — and who may not

It is a weaker fit for investors who need monthly cash flow (TRAX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TRAX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions